Treatment with LIXIANA® does not require routine clinical coagulation monitoring. As a result of Factor Xa inhibition, LIXIANA® prolongs standard clotting tests such as INR, prothrombin time (PT), or activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability. These tests are therefore not recommended to assess the pharmacodynamic effects of LIXIANA®. There are no specific blood tests or assays available for LIXIANA®.

Although treatment with LIXIANA® does not require routine monitoring, the effect on anticoagulation can be estimated by a calibrated quantitative anti-Factor Xa assay which may help to inform clinical decisions in particular situations as, e.g. overdose and emergency surgery.

Reference (click to access full publication)